Management of retinoblastoma in children in Madagascar

  • Randrianarisoa HL Ophthalmologist at Joseph Ravoahangy Andrianavalona University Hospital Center Antananarivo Madagascar
  • Rakotoarisoa RTR Ophthalmologist at Joseph Ravoahangy Andrianavalona University Hospital Center Antananarivo Madagascar
  • Miray LG Ophthalmologist at University Hospital Center of Tambohobe Fianarantsoa Madagascar
  • Rakotomahefa Narison ML Professor in Paediatric at Joseph Ravoahangy Andrianavalona University Hospital Center Antananarivo Madagascar
  • Raobela L Professor in Ophthalmology at Medecine Faculty Antananarivo


Introduction: Retinoblastoma is the most common intraocular tumor in child. The treatment is well codified combining chemotherapy, surgery, radiotherapy and conservative treatment. It involves both the visual and vital prognosis. The aim of this study was to describe epidemiological aspect of retinoblastoma and evaluate therapeutic aspects and evolution of retinoblastoma in Madagascar.

Method: We report in this retrospective study 52 cases found during 5 years, from January 2010 to December 2015. We have collected information about epidemiological and clinical aspect. Delay of diagnosis, treatment done in children and evolution. Data was collected with excel software and analysis was done with Epi info 7.0 software. The quantitative variables were expressed as an average and the qualitative variables as a proportion and percentage.

Result: We had collected 52 cases. The incidence was 10.4 cases per year. Mean age was 3 years, with no gender predominance. More than half or 53.8% (n=28) of children presented minor signs: including leucocoria in 25 children and strabismus in 3 children. Exophthalmos was found in 46.5% (n=24) of cases. Exophthalmia and leukocoria were associated in 6 (10%) children. The delay time before diagnosis was 11 months and 2 days. 39 pieces were sent for examination. Result of Anatomo-pathological study was: 51% (n=20) was undifferentiated retinoblastoma, 36% (n=14) differentiated retinoblastoma, 13% diffused retinoblastoma (n=5) Optic nerve was affected in 7.69% of cases (n=3). Before diagnosis, 55.8% (n=29) of our patients received non-specialized medical treatment and 44.2% (n=23) used traditional treatment. Four patients had primitive enucleation without first chemotherapy. Nine children or 18.75% didn’t have surgical treatment. Neoadjuvant chemotherapy was done in 92.3% (n = 48). 39 patients had first chemotherapy before enucleation. Only 58% of children have received adjuvant chemotherapy. The evolution was marked by 27% (n = 14) of remission, 21% (n = 11) of death and 8% (n = 4) of recurrence. Twenty-three patients (44%) were lost to follow-up.

Conclusion: Diagnosis of retinoblastoma was made in advanced stage. Number of lost to follow-up were high. Treatment consist in chemotherapy and enucleation. Prognosis was worse in Madagascar. Communication with parents, medical personal must recommended to reduce number of children lost to follow-up.

Keywords: Chemotherapy, Enucleation, Retinoblastoma


Download data is not yet available.


1. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009 ; 93(9) : 1129-1131
2. Maillard P, Lupu M, Thomas CD, Misepelter J. Vers un nouveau traitement du rétinoblastome ? Ann Pharm Fr. 2010 ; 68 :195-202
3. Singh AD, Shields CL, Shield JA. Prognostic Factors in Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2000;37(3):134-141
4. Chantada GL, Qaddoumi I, Canturk S, Khetan V, Ma Z. Strategies to manage retinoblastoma in developping countries. Pediatr Blood Cancer. 2011 ; 56 : 341-48
5. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009 Jan;93(1):21-3. doi: 10.1136/bjo.2008.138750
6. Sow AS, Ndoye Roth PA, Moreira C, Diagne Akonde FB, Ka AM et al. Thérapeutique du rétinoblastome : expérience Sénégalaise. J Fr Ophtalmol. 2014 Mai; 37(5): 381-7.
7. Berete CR, Dibi M, Koman E, Atteby Y, Koui S et al. Aspects récents du rétinoblastome en Côte d’Ivoire. Evaluation de 83 cas au CHU de Treichville de 2013-2016. Rev SOAS. 2018; 2 :32-42.
8. Traore F, Togo B, Sylla F, Cheick TB, Diakité AA, Dicko T et al. Retinoblastoma: inventory in Mali and program to develop early diagnosis, treatments and rehabilitation. Bull Cancer. 2013 ;100(2):165-5.
9. Doz F. Aspects récents du rétinoblastome. Arch Ped. 2006 ;13:1329-1336.
10. Nyawira G, Kahaki K, Kariuki-Wanyoike M. Survival among retinoblastoma patients at the Kenyatta National Hospital. J Ophtalmol East cent south Afr. 2013;1:16-9.
11. Butros LJ, Abramson DH, Dunkel IJ. Delayed Diagnosis of Retinoblastoma: Analysis of Degree, Cause, and Potential Consequences. Pediatrics. 2002 ; 109(3) : 1-5
12. Sidibé H. Etude des aspects épidémio-cliniques du rétinoblastome dans le service de Pédiatrie du Centre Hospitalier Universitaire Gabriel Touré (2005-2007) [Thèse]. Médecine Humaine: Bamako; 2009. 302p.
13. Dimaras H, Kimani K, Dimba EA. Retinoblastoma. Lancet. 2012 ; 379 :1436-46
14. Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma following primary enucleation. J Clin Oncol. 2013 ; 31 : 1458-63.
15. Bellaton E, Bertozzi AI, Behar C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol. 2003 ; 87 : 327-9.
16. Kaka HY, Sylla F, Ali MH, Amza A. Les particularités du rétinoblastome au Niger. Eur Sci J. 2016 ; 12(3) : 84-91.
17. El Kettani A, Aderdour S, Daghouj G, Knari S, Zaghloul K et al. Rétinoblastome : résultats préliminaires du protocole national de prise en charge au CHU de Casablanca. J Fr Ophtalmol. 2014;37:115-124.
18. Jehanne M, Brisse H, Gauthier-Villars M, Lumbroso-le Rouic,Paul L, Freneaux P et al. Rétinoblastome : les avancées récentes. Bull cancer. 2014 ;101(4):380-7.
98 Views | 73 Downloads
How to Cite
Randrianarisoa , H. L., R. Rakotoarisoa, L. Miray, M. Rakotomahefa Narison, and L. Raobela. “Management of Retinoblastoma in Children in Madagascar”. World Journal of Current Medical and Pharmaceutical Research, Vol. 4, no. 5, Oct. 2022, pp. 127-30, doi:10.37022/wjcmpr.v4i5.230.
Research Articles